Le Lézard
Classified in: Covid-19 virus
Subject: Lawsuit

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Oscar Health, Inc. (OSCR) Investors


The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Oscar Health, Inc. ("Oscar" or the "Company") (NYSE: OSCR) Class A common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with the Company's March 2021 initial public offering ("IPO" or the "Offering"). Oscar investors have until July 11, 2022, to file a lead plaintiff motion.

If you are a shareholder who suffered a loss, click here to participate.

In March 2021, Oscar conducted its IPO, selling 36,391,946 shares of Class A common stock at a price of $39.00 per share.

On November 10, 2021, Oscar disclosed that its third quarter 2021 medical loss ratio ("MLR") increased 920 basis points year-over-year, to 99.7%. The Company claimed that the MLR increase was "primarily driven by higher net COVID costs as compared to the net benefit in 3Q20, an unfavorable prior year Risk Adjustment Data Validation (RADV) result, and the impact of significant SEP membership growth." The Company also disclosed that its net loss for the quarter was $212.7 million, an increase of $133.6 million year-over-year.

On this news, Oscar's share price fell $4.05 per share, or 24.5%, to close at 12.47 per share on November 11, 2021.

By the commencement of this action, Oscar stock has traded as low as $5.76 per share, a more than 85% decline from the $39.00 per share IPO price.

The complaint filed in this class action alleges that the Registration Statement was materially false and misleading and omitted to state: (1) that Oscar was experiencing growing COVID-19 testing and treatment costs; (2) that Oscar was experiencing growing net COVID costs; (3) that Oscar would be negatively impacted by an unfavorable prior year Risk Adjustment Data Validation (RADV) result relating to 2019 and 2020; (4) that Oscar was on track to be negatively impacted by significant SEP membership growth; and (5) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you purchased Oscar Class A common stock, during the Class Period, you may move the Court no later than July 11, 2022, to ask the Court to appoint you as lead plaintiff. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you purchased Oscar Class A common stock, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to [email protected], or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.


These press releases may also interest you

at 07:15
Draganfly Inc. ("Draganfly" or the "Company"), an award-winning, industry-leading drone solutions and systems developer is pleased to announce a strategic collaboration with ParaZero Technologies Ltd., a pioneer in drone safety systems aimed at...

at 07:05
LiveWire Group, Inc. ("LiveWire" or the "Company") today reported first quarter 2024 results. "We are pleased with the successful launch of the S2 Mulholland, and with three bikes in market, we are proud that LiveWire is now the #1 on-road...

at 07:05
Newmont Corporation (Newmont or the Company) today announced first quarter 2024 results and declared a first quarter dividend of $0.25 per share. "Newmont delivered a strong first quarter operational performance, producing 2.2 million gold...

at 07:05
Can-Fite BioPharma Ltd. , a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced it published an article in the Experimental and Therapeutic Medicine...

at 07:03
Key takeaways Projected return on investment in pharma research and development (R&D) in 2023 has risen to 4.1%, climbing back from 2022's record low of 1.2%.The leading 20 global pharmaceutical companies collectively spent $145 billion on R&D in...

at 07:00
Harley-Davidson, Inc. ("Harley-Davidson," "HDI," or the "Company")  today reported first quarter 2024 results. "Harley-Davidson delivered a good start to the year with a six percent retail growth in North America, our largest and most important...



News published on and distributed by: